WallStSmart

Absci Corp (ABSI)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 3674724% more annual revenue ($57.36B vs $1.56M). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).

ABSI

Avoid

20

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: -0.85

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 5.5
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABSISignificantly Overvalued (-65.6%)

Margin of Safety

-65.6%

Fair Value

$1.57

Current Price

$7.51

$5.94 premium

UndervaluedFair: $1.57Overvalued
NVSSignificantly Overvalued (-56.8%)

Margin of Safety

-56.8%

Fair Value

$95.95

Current Price

$150.47

$54.52 premium

UndervaluedFair: $95.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABSI1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

ABSI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.74B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.3/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Debt/EquityHealth
1.303/10

Elevated debt levels

PEG RatioValuation
3.812/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABSI

The strongest argument for ABSI centers on Debt/Equity.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bear Case : ABSI

The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ABSI carries more volatility with a beta of 2.19 — expect wider price swings.

NVS is growing revenue faster at 4.7% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (48/100 vs 20/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Absci Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?